ASDA Partners With Avery Berkel and Hanshow to Enhance UK Sustainability and Supermarket Shopping Experience
ASDA, in partnership with Avery Berkel and Hanshow, has launched a strategic project to create the first sustainability trial store in the UK that utilizes leading ESL technology and digital retail solutions to enhance operations and improve the shopping experience for customers. This partnership aims to promote refillable solutions for supermarket shopping in the UK, with a focus on sustainability and customer experience. Avery Berkel and Hanshow collaborated to leverage their expertise in retail scales, enterprise scale management, and electronic shelf labels (ESLs) to develop a sustainable solution for the Middleton store, eliminating the need for physical labels and creating a zero-waste solution for ASDA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713235215/en/
Avery Berkel and Hanshow's solutions installed in ASDA (Photo: Business Wire)
The solutions offered by Avery Berkel and Hanshow allow ASDA to carry out its commitment to zero-waste shopping through its bring-your-own-container solution and promoting its ‘Refill Price Promise’ program, which guarantees lower prices to help customers shop more sustainably. ESL technology reduces the cost and time of manual updates, while allowing ASDA to make real-time changes to prices and promotions. It also allows customers to see price differences in wrapped and unwrapped versions of the same product. The solutions make it easier for customers to shop sustainably and are part of a greater effort to make ASDA’s refill areas more efficient and green.
Avery Berkel and Hanshow’s ESL technology streamlines in-store change administration and management, ensuring real-time price and product updates to keep shelves up to date and compliant with regulations. This flexibility to adjust prices and promotions enables retailers to respond promptly to market trends and customer demands, while reducing costs associated with label stock holding and consumables. Increased productivity and efficiency allow employees to focus on providing better customer service.
Customizability is another key feature of the ESL technology innovations, enabling ASDA and other retailers to incorporate custom fonts, images, logos, and graphics into the labels. This allows for brand alignment and a consistent visual identity across stores. The on-screen barcodes and QR codes facilitate easy scanning, streamlining checkout processes and enhancing operational efficiency.
The components of Avery Berkel and Hanshow’s solution are seamlessly integrated to provide shoppers with an enriching refill experience while emphasizing sustainability. Unlike standard printed shelf and product labels, the total refill solution offers additional product information such as refill instructions, ingredients, allergens, and storage details, encouraging sustainability in ASDA stores.
Avery Berkel and Hanshow aimed to revolutionize the shopping experience by making sustainable choices more accessible and engaging for customers. The shopper interface, designed to be simple and intuitive, ensures that even customers unfamiliar with this technology can easily navigate and participate. The collaboration among ASDA, Avery Berkel and Hanshow has led to a total solution that not only benefits the retail industry and its customers, but also provides a green solution and encourages more environmentally friendly retail practices and shopping habits. Consumer demand for sustainable retail will continue to grow in the future. Hanshow will strive to provide the sustainable retail solutions by continuously innovating and improving their digital labelling technology to meet the changing needs of customers and reduce environmental impact.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230713235215/en/
Contact information
Zishan Cai
zishan.cai@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom